References
- Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8(5):520–530.,
- Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(2):e2504.
- Benes H, Garcia-Borreguero D, Ferini-Strambi L, et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13(6):589–597.,
- Garcia-Borreguero D, Hogl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27(2):277–283.,
- Ondo WG, He Y, Rajasekaran S, et al. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord. 2000;15(1):154–158.,
- Qu S, Le W, Zhang X, et al. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol. 2007;66(5):383–388.,
- Zhao H, Zhu W, Pan T, et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res. 2007;85(5):1065–1076.
- Luo F, Li C, Ondo WG, et al. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model. Sleep Med. 2011;12(1):41–46.,
- Ecopipam Investigator’s Brochure.
- Clemens S, Belin-Rauscent A, Simmers J, et al. Opposing modulatory effects of D1- and D2-like receptor activation on a spinal central pattern generator. J Neurophysiol. 2012;107(8):2250–2259.